M&A Deal Summary |
|
|---|---|
| Date | 2025-11-25 |
| Target | Enci Therapeutics |
| Sector | Life Science |
| Buyer(s) | Innova Therapeutics |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Sector | Life Science |
Innova Therapeutics is a biotechnology company focused on developing novel monoclonal-antibody therapies for solid and hematological cancers. The Company’s lead program is IVT-8086, a humanized antibody targeting the protein SFRP2, which is expressed at high levels in many tumors and correlates with patient outcomes. Innova Therapeutics is based in Mt. Pleasant, South Carolina.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| State: South Carolina M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
